ACER Acer Therapeutics Inc.

4.12
-15.16  -79%
Previous Close 19.28
Open 5.34
Price To Book 1.1
Market Cap 41,559,936
Shares 10,087,363
Volume 5,489,898
Short Ratio
Av. Daily Volume 194,337

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued June 25, 2019.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
Pivotal bridging trial to be initiated 4Q 2019 with NDA filing 1Q 2020.
ACER-001
Urea cycle disorder (UCD)

Latest News

  1. Acer Plummets After FDA Declines to OK Rare Genetic Disorder Treatment
  2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acer Therapeutics Inc. (ACER)
  3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acer Therapeutics Inc. - ACER
  4. Acer Therapeutics stock plummets 80 percent on FDA rejection
  5. Acer Therapeutics stock loses over 80% of its value after receiving CRL from FDA for Edsivo
  6. FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder
  7. UPDATE 2-FDA declines to approve Acer Therapeutics' rare genetic disorder treatment
  8. Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients
  9. Wedbush Remains Bullish On Acer Therapeutics, Says Edsivo Review Appears On Track
  10. Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting
  11. Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
  12. Acer Therapeutics to Present at Upcoming Investor Conferences
  13. Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Acer Therapeutics to Present at UBS Global Healthcare Conference
  15. Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data
  16. Introducing Acer Therapeutics (NASDAQ:ACER), A Stock That Climbed 27% In The Last Year
  17. Acer Therapeutics to Participate in Upcoming Investor Conferences
  18. Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  19. Acer Therapeutics Announces In-license of Osanetant from Sanofi
  20. Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance